Molecular and Genetic Medicine

Cutaneous Toxicity from Epidermal Growth Factor Receptor Inhibitors: A Report of Two Cases

Abstract

Rosa VDL, Marota EP, Da Mata JC, Sampaio MM and De Oliveira JR

Epidermal growth factor inhibitors are currently an essential treatment for many advance-stage epithelial cancers as colorectal and lung cancer. Although they are safe, these agents often present cutaneous adverse events that can cause dosage reduction, interruption of treatment and psychosocial discomfort. We report two cases of cutaneous toxicity in patients with solid tumors using different epidermal growth factor inhibitors.